Dupilumab for tough stomach and gut diseases
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This trial tests if dupilumab can help people with hard-to-treat stomach ulcers linked to eosinophilic gastrointestinal disorders (EGIDs), where a type of white blood cell builds up in the gut. It may offer a new option for those who haven't gotten better with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with peptic ulcers that don't improve with standard treatment.
- You also have eosinophilic gastrointestinal disorders (EGIDs) that are hard to treat.
- You do not currently have an active H. pylori infection.
- You do not have inflammatory bowel disease (such as Crohn's or colitis).
- You do not have a parasite infection.
- You do not have cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
Hear when a new Eosinophilic Gastrointestinal Disorders (EGIDs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.